Abstract
Solvay is developing SLV-308 (SME-308), a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties, for the potential oral treatment of Parkinson's disease (PD), panic and depression. By January 2001, SLV-308 had entered phase II trials for PD and phase I trials for anxiety and depression.
MeSH terms
-
Animals
-
Antiparkinson Agents / chemical synthesis
-
Antiparkinson Agents / therapeutic use*
-
Benzoxazoles / chemistry
-
Benzoxazoles / therapeutic use
-
Clinical Trials as Topic / statistics & numerical data
-
Drugs, Investigational / chemical synthesis
-
Drugs, Investigational / therapeutic use*
-
Humans
-
Parkinson Disease / drug therapy*
-
Piperazines / chemistry
-
Piperazines / therapeutic use
-
Technology, Pharmaceutical / methods
Substances
-
Antiparkinson Agents
-
Benzoxazoles
-
Drugs, Investigational
-
Piperazines
-
pardoprunox